(0.26%) 5 112.99 points
(0.28%) 38 347 points
(0.27%) 15 971 points
(-0.94%) $83.06
(5.51%) $2.03
(0.37%) $2 355.80
(0.41%) $27.65
(3.95%) $958.50
(-0.21%) $0.933
(-0.37%) $10.98
(-0.53%) $0.796
(1.69%) $93.43
Live Chart Being Loaded With Signals
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD)...
Stats | |
---|---|
本日の出来高 | 1.79M |
平均出来高 | 1.22M |
時価総額 | 9.56B |
EPS | $-0.860 ( 2023-08-10 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -56.47 |
ATR14 | $2.40 (1.20%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-06-16 | Hendrix Martin | Sell | 2 071 | Common Stock |
2023-06-16 | Hendrix Martin | Sell | 40 000 | Stock Option (right to buy) |
2023-06-16 | Hendrix Martin | Sell | 20 500 | Stock Option (right to buy) |
2023-06-16 | Laur James | Sell | 2 071 | Common Stock |
2023-06-16 | Laur James | Sell | 40 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
-86.77 |
Last 100 transactions |
Buy: 394 552 | Sell: 5 154 734 |
ボリューム 相関
Prometheus Biosciences, 相関
10 最も正の相関 | |
---|---|
AVEO | 0.965 |
ITMR | 0.949 |
HZNP | 0.941 |
DVCR | 0.939 |
MLCO | 0.932 |
OPNT | 0.932 |
AVAC | 0.929 |
LUNA | 0.925 |
EWEB | 0.923 |
ALXN | 0.914 |
10 最も負の相関 | |
---|---|
HLXA | -0.95 |
THTX | -0.933 |
ENPH | -0.932 |
XFOR | -0.931 |
AVO | -0.93 |
GRIN | -0.924 |
GOSS | -0.917 |
ATAI | -0.912 |
ZSAN | -0.907 |
CFBK | -0.906 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Prometheus Biosciences, 相関 - 通貨/商品
Prometheus Biosciences, 財務諸表
Annual | 2023 |
収益: | $6.81M |
総利益: | $6.81M (100.00 %) |
EPS: | $-3.49 |
FY | 2023 |
収益: | $6.81M |
総利益: | $6.81M (100.00 %) |
EPS: | $-3.49 |
FY | 2022 |
収益: | $3.13M |
総利益: | $3.13M (100.00 %) |
EPS: | $-2.87 |
FY | 2020 |
収益: | $1.23M |
総利益: | $0.00 (0.00 %) |
EPS: | $-1.376 |
Financial Reports:
No articles found.
Prometheus Biosciences,
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; PR1800, an anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。